esophageal cancer
Lucid Diagnostics Partners With Front Line Mobile to Promote Esophageal Cancer Test
Working with the first responder medical care provider, Lucid is planning high-volume testing events among firefighters and other frontline workers with elevated risk.
Previse Completes Validation Study of Barrett's Esophagus Test, Sees Path to Guideline Inclusion
Premium
The epigenetic risk stratification test demonstrated the potential to decrease surveillance among some patients and increase it among others.
Lucid Diagnostics' Esophageal Precancer Test Sales Spike in Q2
The firm's revenues, all from the EsoGuard DNA screening test, increased to $976,000 in Q2 compared to $159,000 in the same quarter last year.
Castle Bio Q4, Full-Year 2023 Revenues Jump on Strong Test Volume Growth
The company delivered 20,284 total test reports in Q4, up 60 percent from 12,644 in the year-ago quarter, reflecting growth across nearly all of its diagnostic test categories.
Previse Ramps up Commercialization of Barrett's Esophagus Test, Developing Esophageal Cancer Assay
Premium
The company currently offers a risk stratification test for Barrett's esophagus and is developing an early detection test for esophageal cancer.